The relationship between pan-immune-inflammation value and survival outcomes in patients with metastatic renal cell carcinoma treated with nivolumab in the second line and beyond: a Turkish oncology group kidney cancer consortium (TKCC) study

Basit Öğe Kaydı
dc.authoridErturk, Ismail/0000-0001-6835-0988
dc.authoridYekedüz, Emre/0000-0001-6819-5930
dc.authoridÖksüzoğlu Çakmak, Ömür Berna/0000-0002-2756-8646
dc.authoridEROL, CİHAN/0000-0003-3155-8798
dc.authoridAksoy, Sercan/0000-0003-4984-1049;
dc.authorwosidSendur, Mehmet Ali Nahit/H-7555-2014
dc.authorwosidErturk, Ismail/B-4317-2019
dc.authorwosidYekedüz, Emre/ABA-5814-2020
dc.authorwosidKüçükarda, Ahmet/AGF-2120-2022
dc.authorwosidÖksüzoğlu Çakmak, Ömür Berna/HKN-6428-2023
dc.authorwosidEROL, CİHAN/GWU-8797-2022
dc.authorwosidAksoy, Sercan/S-2480-2019
dc.contributor.authorYekeduz, Emre
dc.contributor.authorTural, Deniz
dc.contributor.authorErturk, Ismail
dc.contributor.authorKarakaya, Serdar
dc.contributor.authorErol, Cihan
dc.contributor.authorErcelep, Ozlem
dc.contributor.authorArslan, Cagatay
dc.date.accessioned2024-06-12T11:03:43Z
dc.date.available2024-06-12T11:03:43Z
dc.date.issued2022
dc.departmentTrakya Üniversitesien_US
dc.description.abstractBackground Pan-immune-inflammation value (PIV) is an easily accessible immune marker based on peripheral blood to estimate prognosis in patients with cancer. This study evaluates the prognostic value of PIV in patients with metastatic renal cell carcinoma (mRCC) treated with nivolumab. Methods In this retrospective cohort study, patients with mRCC treated with nivolumab in the second line and beyond were selected from the Turkish Oncology Group Kidney Cancer Consortium (TKCC) database. PIV was calculated using the following formula: neutrophil -(10(3)/mm(3)) x monocyte -(10(3)/mm(3)) x platelet-(10(3)/mm(3))/lymphocyte -(103/mm(3)). Results A total of 152 patients with mRCC were included in this study. According to cut-off value for PIV, 77 (50.7%) and 75 (49.3%) patients fell into PIV-low (<= 372) and PIV-high (> 372) groups, respectively. In multivariate analysis, PIV-high (HR: 1.64, 95% CI 1.04-2.58, p = 0.033 for overall survival (OS); HR: 1.55, 95% CI 1.02-2.38, p = 0.042 for progression-free survival (PFS)) was independent risk factor for OS and PFS after adjusting for confounding variables, such as performance score, the International mRCC Database Consortium (IMDC) risk score, and liver metastasis. Conclusion This study established that pre-treatment PIV might be a prognostic biomarker in patients with mRCC treated with nivolumab in the second line and beyond.en_US
dc.identifier.doi10.1007/s00432-022-04055-5
dc.identifier.endpage3546en_US
dc.identifier.issn0171-5216
dc.identifier.issn1432-1335
dc.identifier.issue12en_US
dc.identifier.pmid35616728en_US
dc.identifier.scopus2-s2.0-85130706906en_US
dc.identifier.scopusqualityQ1en_US
dc.identifier.startpage3537en_US
dc.identifier.urihttps://doi.org/10.1007/s00432-022-04055-5
dc.identifier.urihttps://hdl.handle.net/20.500.14551/21766
dc.identifier.volume148en_US
dc.identifier.wosWOS:000800433700002en_US
dc.identifier.wosqualityQ2en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherSpringeren_US
dc.relation.ispartofJournal Of Cancer Research And Clinical Oncologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectImmunotherapyen_US
dc.subjectRenal Cell Carcinomaen_US
dc.subjectBiomarkeren_US
dc.subjectTo-Lymphocyte Ratioen_US
dc.subjectIndex Siien_US
dc.subjectPrognostic-Factorsen_US
dc.subjectTherapiesen_US
dc.subjectMrccen_US
dc.titleThe relationship between pan-immune-inflammation value and survival outcomes in patients with metastatic renal cell carcinoma treated with nivolumab in the second line and beyond: a Turkish oncology group kidney cancer consortium (TKCC) studyen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu